Functional Pathway Analysis Using SCNP of FLT3 Receptor Pathway Deregulation in AML Provides Prognostic Information Independent from Mutational Status

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Cesano, Alessandra ^a   Putta, Santosh ^a   Rosen, David B ^a   Cohen, Aileen C ^a   Gayko, Urte ^a   Mathi, Kavita ^a   Woronicz, John ^a   Hawtin, Rachael E ^a   Cripe, Larry ^b,c   Sun, Zhuoxin ^b,d   Tallman, Martin S ^b,e   Paietta, Elisabeth ^b,f  

^a Nodality Inc   (United States)

^b Eastern Cooperative Oncology Group (ECOG)   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CASE REPORT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FMS LIKE4 TYROSINE KINASE 3 RECEPTOR GENE; GENE; GENE MUTATION; HUMAN; MALE; MUTATIONAL ANALYSIS; NUCLEOPHOSMIN GENE; PREDICTIVE VALUE; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SINGLE CELL ANALYSIS; SURVIVAL TIME; WILD TYPE;

AGED; AGED, 80 AND OVER; APOPTOSIS; CELLS, CULTURED; DISEASE-FREE SURVIVAL; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTAGENESIS; MUTATION; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS; SIGNAL TRANSDUCTION; SINGLE-CELL ANALYSIS;

EID: 84874203549     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056714     Document Type: Article

References (55)

1. Krause DS, Van Etten RA, (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353: 172-187.
2. Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, et al. (2001) Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res 61: 7233-7239.
3. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, et al. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98: 1752-1759.
4. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, et al. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99: 4326-4335.
5. Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, et al. (2002) Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 100: 4372-4380.
6. Gale RE, Hills R, Kottaridis PD, Srirangan S, Wheatley K, et al. (2005) No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood 106: 3658-3665.
7. Beran M, Luthra R, Kantarjian H, Estey E, (2004) FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype. Leuk Res 28: 547-550.
8. Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, et al. (2001) Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 97: 89-94.
9. Kondo M, Horibe K, Takahashi Y, Matsumoto K, Fukuda M, et al. (1999) Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Med Pediatr Oncol 33: 525-529.
10. Iwai T, Yokota S, Nakao M, Okamoto T, Taniwaki M, et al. (1999) Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. Leukemia 13: 38-43.
11. Kindler T, Lipka DB, Fischer T, (2010) FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 116: 5089-5102.
12. Gale RE, Green C, Allen C, Mead AJ, Burnett AK, et al. (2008) The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111: 2776-2784.
13. Schnittger S, Bacher U, Kern W, Alpermann T, Haferlach C, et al. (2011) Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 25: 1297-1304.
14. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, et al. (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352: 254-266.
15. Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, et al. (2006) Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107: 4011-4020.
16. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrozek K, et al. (2010) Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 28: 596-604.
17. Estey EH, (2012) Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. American journal of hematology 87: 89-99.
18. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, et al. (2012) Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 366: 1079-1089.
19. Dosil M, Wang S, Lemischka IR, (1993) Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. Mol Cell Biol 13: 6572-6585.
20. Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, et al. (2000) Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 19: 624-631.
21. Lavagna-Sevenier C, Marchetto S, Birnbaum D, Rosnet O, (1998) FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates. Leukemia 12: 301-310.
22. Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, et al. (2000) Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 96: 3907-3914.
23. Rottapel R, Turck CW, Casteran N, Liu X, Birnbaum D, et al. (1994) Substrate specificities and identification of a putative binding site for PI3K in the carboxy tail of the murine Flt3 receptor tyrosine kinase. Oncogene 9: 1755-1765.
24. Zhang S, Fukuda S, Lee Y, Hangoc G, Cooper S, et al. (2000) Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J Exp Med 192: 719-728.
25. Zhang S, Mantel C, Broxmeyer HE, (1999) Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells. J Leukoc Biol 65: 372-380.
26. Choudhary C, Muller-Tidow C, Berdel WE, Serve H, (2005) Signal transduction of oncogenic Flt3. International Journal of Hematology 82: 93-99.
27. Rosen DB, Minden MD, Kornblau SM, Cohen A, Gayko U, et al. (2010) Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP). PLoS ONE 5: e13543.
28. Cripe LD, Li X, Litzow M, Paietta E, Rowe JM, et al. (2006) A Randomized, Placebo-Controlled, Double Blind Trial of the MDR Modulator, Zosuquidar, during Conventional Induction and Post-Remission Therapy for Pts >60 Years of Age with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS): ECOG 3999. ASH Annual Meeting Abstracts 108: 423.
29. Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, et al. (2004) A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 103: 479-485.
30. Rosen DB, Putta S, Covey T, Huang YW, Nolan GP, et al. (2010) Distinct patterns of DNA damage response and apoptosis correlate with Jak/Stat and PI3kinase response profiles in human acute myelogenous leukemia. PLoS ONE 5: e12405.
31. Kornblau SM, Minden MD, Rosen DB, Putta S, Cohen A, et al. (2010) Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy. Clin Cancer Res 16: 3721-3733.
32. Cheong JW, Eom JI, Maeng HY, Lee ST, Hahn JS, et al. (2003) Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome. Br J Haematol 122: 454-456.
33. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, et al. (2006) Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441: 475-482.
34. Scholl C, Gilliland DG, Fröhling S, (2008) Deregulation of Signaling Pathways in Acute Myeloid Leukemia. Seminars in Oncology 35: 336-345.
35. Lyman SD, Jacobsen SE, (1998) c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 91: 1101-1134.
36. Kikushige Y, Yoshimoto G, Miyamoto T, Iino T, Mori Y, et al. (2008) Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival. J Immunol 180: 7358-7367.
37. Benekli M, Xia Z, Donohue KA, Ford LA, Pixley LA, et al. (2002) Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 99: 252-257.
38. Benekli M, Baer MR, Baumann H, Wetzler M, (2003) Signal transducer and activator of transcription proteins in leukemias. Blood 101: 2940-2954.
39. Baker SJ, Rane SG, Reddy EP, (2007) Hematopoietic cytokine receptor signaling. Oncogene 26: 6724-6737.
40. Bunting KD, (2007) STAT5 signaling in normal and pathologic hematopoiesis. Front Biosci 12: 2807-2820.
41. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
42. Stelzer GT, Goodpasture L (2000) Use of multiparameter flow cytometry and immunophenotyping for the diagnosis and classification of acute myeloid leukemia. In: Stewart CC, Nicholson JKA, editors. Immunophenotyping. Wilmington DE: Wiley-Liss. pp. 215-238.
43. Cesano A, Putta S, Gayko U, Hackett J, Rosen DB, et al. (2010) Single-Cell Network Profiliing (SCNP) Signatures Independently Predict Response to Induction Therapy In Older Patients with Acute Myeloid Leukemia (AML). ASH Annual Meeting Abstracts 116: 2695.
44. Cesano A, Rosen DB, O'Meara P, Putta S, Gayko U, et al. (2012) Functional pathway analysis in acute myeloid leukemia using single cell network profiling assay: effect of specimen source (bone marrow or peripheral blood) on assay readouts. Cytometry Part B, Clinical cytometry 82: 158-172.
45. Shults KE, Miller DT, Davis BH, Flye L, Hobbs LA, et al. (2006) A standardized ZAP-70 assay-lessons learned in the trenches. Cytometry B Clin Cytom 70: 276-283.
46. Purvis N, Stelzer G, (1998) Multi-platform, multi-site instrumentation and reagent standardization. Cytometry 33: 156-165.
47. Wang L, Gaigalas AK, Marti G, Abbasi F, Hoffman RA, (2008) Toward quantitative fluorescence measurements with multicolor flow cytometry. Cytometry A 73: 279-288.
48. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, et al. (1999) Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93: 3074-3080.
49. Gorello P, Cazzaniga G, Alberti F, Dell'Oro MG, Gottardi E, et al. (2006) Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 20: 1103-1108.
50. Jolliffe IT (2002) Principal Component Analysis. Springer, NY. 487 p.
51. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, et al. (2001) The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98: 1312-1320.
52. O'Donnell MR, Abboud CN, Altman JK, Appelbaum FR, Arber DA, et al. (2012) NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. In: Network NCC, editor. Version 2.2012 ed.
53. Sallmyr A, Fan J, Datta K, Kim KT, Grosu D, et al. (2008) Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. Blood 111: 3173-3182.
54. Fan J, Li L, Small D, Rassool F, (2010) Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy. Blood 116: 5298-5305.
55. Brown P, Meshinchi S, Levis M, Alonzo TA, Gerbing R, et al. (2004) Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. Blood 104: 1841-1849.